BioMarin Posts $122.8 Million Third-Quarter Loss
The rare disease drugmaker reported a wider-than-expected quarterly loss even as adjusted earnings came in positive.
Updated on Nov. 2, 2026 in Economic Indicators
BioMarin Pharmaceutical reported a $122.8 million loss in its third quarter, or 63 cents per share, while adjusted earnings were 23 cents per share. Third-quarter revenue reached $1.02 billion, according to the company's results released Monday.
Why it matters
The gap between the reported loss and adjusted profit highlights how one-time and non-cash items shape headline results for biopharmaceutical companies. Investors are watching whether revenue growth can offset those charges as the company guides for full-year performance.
BioMarin's third-quarter net loss was $122.8 million, or 63 cents per share, compared with an analyst expectation of a 9-cent loss per share. Third-quarter revenue of $1.02 billion slightly missed the $1.03 billion analysts expected, and the company did not explain the GAAP-to-adjusted gap in the reported figures.
The players
BioMarin Pharmaceutical
A San Rafael, California-based biopharmaceutical company focused on developing treatments for rare genetic diseases.
The details
BioMarin, a San Rafael, California-based rare disease biopharmaceutical company, released its third-quarter results on Monday. The company now expects full-year earnings of $2.80 to $3.10 per share and full-year revenue of $3.8 billion to $3.9 billion.
Timeline
Third quarter (2026): BioMarin's reported loss and revenue period.
Monday, November 2, 2026: Third-quarter earnings released.
Market Landscape
BioMarin's results were measured against Zacks Investment Research consensus, with the reported loss far wider than the 9-cent loss analysts expected. Revenue came in just below the $1.03 billion Zacks consensus, placing the rare disease drugmaker in a mixed position relative to Street expectations this quarter.
For investors holding BioMarin shares, the stock closed at $57.56 and is down 3% year to date but up about 7% over the past 12 months. Retail shareholders should weigh the wider-than-expected quarterly loss against the company's reaffirmed full-year guidance.
The takeaway
Adjusted earnings and GAAP results can tell very different stories for drugmakers, so readers should check both before drawing conclusions about a company's health. Comparing reported figures against analyst expectations helps show whether a quarter was a surprise.
Further reading
For broader context on how company earnings fit into state-level trends, explore Economic Indicators coverage.
